Arvinas

Arvinas

Develops therapies targeting disease-causing proteins

About Arvinas

Simplify's Rating
Why Arvinas is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

201-500

Company Stage

IPO

Headquarters

New Haven, Connecticut

Founded

2013

Overview

Arvinas develops therapies aimed at treating serious diseases caused by harmful proteins. Their main product, PROTAC® protein degraders, works by using the body's natural system to eliminate these proteins selectively. This approach allows for targeted treatment of conditions like cancer and neurodegenerative disorders. Unlike many other biopharmaceutical companies, Arvinas focuses specifically on protein degradation, which sets them apart in the biotechnology field. Their goal is to enhance patient outcomes by creating effective therapies that tackle the root causes of diseases.

Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase 3 trial of vepdegestrant enhances Arvinas's leadership in protein degradation.
  • Expansion at Science Park indicates growth and increased R&D capabilities.
  • Strategic executive appointments strengthen financial and commercial operations.

What critics are saying

  • Increased competition in the PROTAC space may impact Arvinas's market share.
  • Potential regulatory scrutiny could delay clinical trials and drug approvals.
  • Dependence on partnerships poses risks if collaborations face challenges.

What makes Arvinas unique

  • Arvinas uses PROTAC technology to target disease-causing proteins for degradation.
  • The company focuses on innovative therapies for cancer and neurodegenerative disorders.
  • Arvinas collaborates with major pharmaceutical companies like Pfizer and Novartis.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$585.9M

Above

Industry Average

Funded Over

5 Rounds

Private Placement VC funding comparison data is currently unavailable. We're working to provide this information soon!
Private Placement VC Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
PharmiWeb
Mar 12th, 2025
Arvinas And Pfizer Announce Positive Topline Results From Phase 3 Veritac-2 Clinical Trial

– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival –– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefitin a Phase 3 trial –NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader.The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population

Investing.com
Jan 10th, 2025
Arvinas outlines 2025 clinical trial plans for breast cancer drug

In a corporate update, Arvinas announced the appointment of Alex Santini as interim Chief Commercial Officer, effective January 17, 2025.

Hartford Business Journal
Dec 18th, 2024
New Haven-based Arvinas to expand Science Park footprint; renews leases

Arvinas said it will also add 1,500 square feet of space at 5 Science Park for a total of 64,000 square feet.

TipRanks
Jun 24th, 2024
Arvinas Appoints Andrew Saik as CFO with Equity Incentives

Arvinas appoints Andrew Saik as CFO with equity incentives.

Yahoo Finance
Jun 17th, 2024
Arvinas Announces Promotions Of Ian Taylor, Ph.D. To President Of Research And Development And Angela Cacace, Ph.D. To Chief Scientific Officer

Arvinas Inc.Ian Taylor, Ph.D.President of Research and Development at Arvinas, Inc.Angela Cacace, Ph.D.Chief Scientific Officer at Arvinas, Inc.NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr

Recently Posted Jobs

Sign up to get curated job recommendations

Arvinas is Hiring for 17 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Arvinas's jobs every few hours, so check again soon! Browse all jobs →